Litium: More Brains, More Geins - Redeye

Redeye provides an update following Litium’s acquisition of Geins, a small but strategically sound deal that brings both technical capabilities and a customer base of some 25 clients. The transaction adds ~11% to ARR and the 6% rights issue discount and broad insider participation reflect strong backing. We lift our estimates slightly across the board.

Länk till analysen i sin helhet: https://www.redeye.se/research/1127053/litium-more-brains-more-geins?utm_source=finwire&utm_medium=RSS